Ranolazine: Ion‐channel‐blocking actions and in vivo electrophysiological effects
- 1 August 2004
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 142 (8), 1300-1308
- https://doi.org/10.1038/sj.bjp.0705879
Abstract
Ranolazine is a novel anti-ischemic drug that prolongs the QT interval. To evaluate the potential mechanisms and consequences, we studied: (i) Ranolazine's effects on HERG and IsK currents in Xenopus oocytes with two-electrode voltage clamp; (ii) effects of ranolazine, compared to d-sotalol, on effective refractory period (ERP), QT interval and ventricular rhythm in a dog model of acquired long QT syndrome; and (iii) effects on selected native currents in canine atrial myocytes with whole-cell patch-clamp technique. Ranolazine inhibited HERG and IsK currents with different potencies. HERG was inhibited with an IC(50) of 106 micromol l(-1), whereas the IC(50) for IsK was 1.7 mmol l(-1). d-Sotalol caused reverse use-dependent ERP and QT interval prolongation, whereas ranolazine produced modest, nonsignificant increases that plateaued at submaximal doses. Neither drug affected QRS duration. d-Sotalol had clear proarrhythmic effects, with all d-sotalol-treated dogs developing torsades de pointes (TdP) ventricular tachyarrhythmias, of which they ultimately died. In contrast, ranolazine did not generate TdP. Effects on I(Kr) and I(Ks) were similar to those on HERG and IsK. Ranolazine blocked I(Ca) with an IC(50) of approximately 300 micromol l(-1). I(Na) was unaffected. We conclude that ranolazine inhibits I(Kr) by blocking HERG currents, inhibits I(Ca) at slightly larger concentrations, and has modest and self-limited effects on the QT interval. Unlike d-sotalol, ranolazine does not cause TdP in a dog model. The greater safety of ranolazine may be due to its ability to inhibit I(Ca) at concentrations only slightly larger than those that inhibit I(Kr), thus producing offsetting effects on repolarization.Keywords
This publication has 47 references indexed in Scilit:
- Partial fatty acid oxidation (pFOX) inhibition: A new therapy for chronic stable anginaClinical Cardiology, 2003
- Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserveBritish Journal of Pharmacology, 2002
- A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agentsThe American Journal of Cardiology, 1999
- Polymorphic ventricular tachycardias induced by ?-sotalol and phenylephrine in canine preparations of atrioventricular block: initiation in the conduction system followed by spatially unstable re-entryCardiovascular Research, 1998
- Ranolazine Increases Active Pyruvate Dehydrogenase in Perfused Normoxic Rat Hearts: Evidence for an Indirect MechanismJournal of Molecular and Cellular Cardiology, 1996
- Effect of Ranolazine on Infarct Size in a Canine Model of Regional Myocardial Ischemia/ReperfusionJournal of Cardiovascular Pharmacology, 1994
- Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heartCardiovascular Research, 1994
- Effects of a New Metabolic Modulator, Ranolazine, on Exercise Tolerance in Angina Pectoris Patients Treated with β-Blocker or DiltiazemJournal of Cardiovascular Pharmacology, 1992
- Pharmacological response of quinidine induced early afterdepolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanismsCardiovascular Research, 1988
- Recent Advances in Understanding the Pharmacology of AmiodaroneDrugs, 1988